Evidence map›Paper›PMID 38022675›Full record

ArticleFrontiers in immunology2023

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Jana Mourtada, Christelle Lony, Anaïs Nicol, Justine De Azevedo, Cyril Bour, Christine Macabre, Patrick Roncarati, Sonia Ledrappier, Philippe Schultz, Christian Borel and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Jana Mourtada *Laboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Christelle Lony *Laboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Anaïs NicolLaboratoire de Radiobiologie, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Justine De AzevedoLaboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Cyril BourLaboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Christine MacabreLaboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Patrick RoncaratiLaboratory of Experimental Pathology, GIGA-Cancer, University of Liège, Liège, Belgium.
Sonia LedrappierTumorothèque du Centre Paul Strauss, Centre Paul Strauss, Strasbourg, France.
Philippe SchultzHôpitaux Universitaires de Strasbourg, Department of Otorhinolaryngology and Head and Neck Surgery, Strasbourg, France.
Christian BorelDepartment of Medical Oncology, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Mickaël BurgyDepartment of Medical Oncology, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Bohdan WasylykDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, France.
Georg MellitzerUniversité de Strasbourg-Inserm, UMR_S 1113 IRFAC, Laboratory « Streinth », Strasbourg, France.
Michaël HerfsLaboratory of Experimental Pathology, GIGA-Cancer, University of Liège, Liège, Belgium.
Christian Gaiddon *Université de Strasbourg-Inserm, UMR_S 1113 IRFAC, Laboratory « Streinth », Strasbourg, France.
Alain C Jung *Laboratoire de Biologie Tumorale, Institut de cancérologie Strasbourg Europe, Strasbourg, France.
Inserm · FRInstitut de Cancérologie Strasbourg · FRUniversity of Liège · BECentre National de la Recherche Scientifique · FRHôpitaux Universitaires de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Deconvoluting the heterogenous prognosis of Human Papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OSCC) is crucial for enhancing patient care, given its rapidly increasing incidence in western countries and the adverse side effects of OSCC treatments. Methods: Transcriptomic data from HPV-positive OSCC samples were analyzed using unsupervised hierarchical clustering, and clinical relevance was evaluated using Kaplan-Meier analysis. HPV-positive OSCC cell line models were used in functional analyses and phenotypic assays to assess cell migration and invasion, response to cisplatin, and phagocytosis by macrophages Results: We found, by transcriptomic analysis of HPV-positive OSCC samples, a ΔNp63 dependent molecular signature that is associated with patient prognosis. ΔNp63 was found to act as a tumor suppressor in HPV-positive OSCC at multiple levels. It inhibits cell migration and invasion, and favors response to chemotherapy. RNA-Seq analysis uncovered an unexpected regulation of genes, such as DKK3, which are involved in immune response-signalling pathways. In agreement with these observations, we found that ΔNp63 expression levels correlate with an enhanced anti-tumor immune environment in OSCC, and ΔNp63 promotes cancer cell phagocytosis by macrophages through a DKK3/NF-κB-dependent pathway. Conclusion: Our findings are the first comprehensive identification of molecular mechanisms involved in the heterogeneous prognosis of HPV-positive OSCC, paving the way for much-needed biomarkers and targeted treatment.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsPapillomavirus InfectionsHuman Papillomavirus VirusesHumansPrognosisSquamous Cell Carcinoma of Head and Neckhuman papillomavirusimmune responseoropharyngeal squamous cell carcinomatumor microenvironmentΔNp63

Identifiers

PMID38022675
PMCPMC10630910
OpenAlexW4387937757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.